<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293462</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000459510</org_study_id>
    <secondary_id>UCSF-H452-26184-03</secondary_id>
    <secondary_id>02802</secondary_id>
    <secondary_id>5R01CA107080</secondary_id>
    <nct_id>NCT00293462</nct_id>
  </id_info>
  <brief_title>GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer</brief_title>
  <official_title>Management of Mucositis With GM-CSF (Sargramostim) Mouthwash Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marilyn Dodd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GM-CSF may protect normal cells from the side effects, such as mucositis, of radiation&#xD;
      therapy and may help damaged tissue heal faster after radiation therapy. This randomized&#xD;
      clinical trial is studying how well GM-CSF works in preventing and treating mucositis in&#xD;
      patients who are undergoing radiation therapy for head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the incidence of radiotherapy (RT)-induced oral mucositis of any grade, using&#xD;
           the Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring Criteria (RTOG&#xD;
           ARMSC)-Mucous Membrane, in patients treated with 1 of 2 mouthwashes (sargramostim&#xD;
           [GM-CSF] or salt and soda). (prevention portion of the study)&#xD;
&#xD;
        -  Compare the effectiveness of the 2 mouthwashes in treating oral mucositis as defined by&#xD;
           the incidence of RTOG ARMSC-Mucous Membrane grade 3 and 4 mucositis in patients in 1 of&#xD;
           3 groups (salt and soda, continuing GM-CSF, or new GM-CSF). (treatment portion of the&#xD;
           study)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the effectiveness of the 2 mouthwashes in preventing RT-induced oral mucositis&#xD;
           by the following direct indices:&#xD;
&#xD;
             -  Cumulative RT dose prior to onset of oral mucositis (prevention portion only)&#xD;
&#xD;
             -  Severity of RT-induced oral mucositis at onset and during treatment (using Oral&#xD;
                Mucositis Assessment Scale (OMAS))&#xD;
&#xD;
             -  Severity of oral mucositis-related pain at onset and during treatment (using OMAS)&#xD;
&#xD;
             -  Incidence of oral mucositis-related infection at onset and during treatment (using&#xD;
                OMAS)&#xD;
&#xD;
             -  Severity of oral mucositis-related problems with ingestion of food and fluids at&#xD;
                onset and during treatment (using OMAS)&#xD;
&#xD;
             -  Time to healing of RT-induced oral mucositis.&#xD;
&#xD;
        -  Evaluate patients using the following indirect indices of oral mucositis morbidity&#xD;
           during the prevention and treatment portions of the study.&#xD;
&#xD;
             -  Tolerance to RT regimen&#xD;
&#xD;
             -  Functional status&#xD;
&#xD;
             -  Quality of life.&#xD;
&#xD;
      OUTLINE: This is a multicenter, randomized, controlled, double-blinded study. Patients are&#xD;
      stratified according to radiotherapy dose schedule (standard vs hyperfractionation vs&#xD;
      intensity modulation) and concurrent chemotherapy (yes vs no).&#xD;
&#xD;
        -  Prevention (no mucositis): Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive oral sargramostim (GM-CSF) mouthwash, holding it in their&#xD;
                mouths and swallowing it in intervals over 1 hour once daily.&#xD;
&#xD;
             -  Arm II: Patients receive oral salt and soda mouthwash, holding it and swallowing it&#xD;
                in intervals over 1 hour once daily.&#xD;
&#xD;
      Treatment in both arms continues during 6-7 weeks of radiotherapy and/or the onset of&#xD;
      mucositis. Patients also perform PRO-SELF: Mouth Aware (PSMA) twice daily.&#xD;
&#xD;
        -  Treatment (onset of mucositis): Patients who are currently using GM-CSF mouthwash&#xD;
           continue use as in prevention. Patients who are currently using salt and soda mouthwash&#xD;
           are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm III: Patients receive GM-CSF mouthwash as in arm I.&#xD;
&#xD;
             -  Arm IV: Patients receive salt and soda mouthwash as in arm II. In both arms,&#xD;
                treatment continues until the mucositis heals. Patients perform PSMA four times&#xD;
                daily during and for 3 months after radiotherapy.&#xD;
&#xD;
      Quality of life is assessed at baseline and periodically after radiotherapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed every once a month for 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2005</start_date>
  <completion_date type="Actual">December 31, 2009</completion_date>
  <primary_completion_date type="Actual">December 31, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Number of Participants With Grade 1 or 2 Oral Mucositis (GM-CSF and SS Groups Only)</measure>
    <time_frame>From baseline to onset of mucositis, approximately 16 days</time_frame>
    <description>The number of participants with recorded grade 1 (mild; Irritation, may experience slight pain, not requiring analgesic) or grade 2 (moderate; Patchy mucositis that may produce inflammatory serosanguinitis discharge; may experience moderate pain requiring analgesia) oral mucositis using the Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria Oral Mucosa Assessment Scale at baseline and during radiotherapy will be recorded. The RTOG grading is reliant on a clinician's ability to judge the anatomical changes associated with oral mucositis (size and characteristics of ulceration), with symptoms ranging from Grade 0 (no symptoms) to Grade 4 (Ulceration, hemorrhage, or necrosis). A comparison of incidence in the GM-CSF Group (GG) and Arm II: Salt &amp; Soda Group (SS) will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the Mean Number of Days for Mucositis to Heal Across by Group</measure>
    <time_frame>From onset of mucositis to healing of mucositis, approximately 80 days</time_frame>
    <description>The mean number of days for mucositis to heal will be used to evaluate the effectiveness of the two mouthwashes in treating oral mucositis as defined by the incidence of Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Combined Mean Score on the Overall Quality of Life Questionnaires by Group</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Quality of life at baseline, during radiotherapy, and once a month for 3 months after radiotherapy. The items on the quality of life questionnaire developed for the study range in scores from 0-10 with higher scores indicating a better quality of life. Scores at all time points were combined to compute one mean score for overall quality of life during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Combined Mean Score on the Karnofsky Performance Status Scale (KPS) by Group</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Functional status of participants was measured by administering the KPS which contains items asking about performing daily activities. The scores are grouped in 10s ranging from 100 (Normal, no complaints) to 0 (Dead), with higher scores indicating better functional status. The KPS was administered at baseline, during radiotherapy, and once a month for 3 months after radiation therapy. Scores at all time points were combined to compute one mean to determine overall performance status during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Combined Mean Score on the Pain Questionnaire by Group</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Severity and quality of pain was measured using a pain questionnaire developed for this study with total scores ranging from 0 (no pain) to 10 (most intense pain) with higher scores indicating a greater level of pain. The questionnaire was administered at baseline, during radiotherapy, and once a month for 3 months after radiotherapy. Scores at all time points were combined to compute one mean to determine overall pain intensity score during the course of the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Mucositis Oral</condition>
  <condition>Radiation Toxicity</condition>
  <condition>Tongue Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I: GM-CSF Group (GG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm I: Patients were randomized to receive oral sargramostim (GM-CSF) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II: Salt &amp; Soda Group (SS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm II: Patients were randomized to receive salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving SS treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III: Salt &amp; Soda Switched to GM-CSF (SG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm III: Patients were randomized to receive oral salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <arm_group_label>Arm I: GM-CSF Group (GG)</arm_group_label>
    <arm_group_label>Arm III: Salt &amp; Soda Switched to GM-CSF (SG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oral salt and soda mouthwash</intervention_name>
    <description>Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily.</description>
    <arm_group_label>Arm II: Salt &amp; Soda Group (SS)</arm_group_label>
    <arm_group_label>Arm III: Salt &amp; Soda Switched to GM-CSF (SG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Histopathologically confirmed diagnosis of head and neck cancer&#xD;
&#xD;
          -  Scheduled to undergo continuous course of conventional or hyperfractionated&#xD;
             radiotherapy or intensity-modulated radiotherapy (IMRT) with or without concurrent&#xD;
             chemotherapy&#xD;
&#xD;
          -  Planning to receive a total radiation dose ≥ 5,500 centigray (cGy), administered in a&#xD;
             single daily fraction of 180-220 cGy (5 days a week) or twice daily fractions of&#xD;
             110-150 cGy&#xD;
&#xD;
          -  Normal baseline oral examinations (no pre-existing lesion)&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Mentally capable of participating in research protocol&#xD;
&#xD;
          -  Expected survival &gt; 4.5 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) &lt; 5 times upper limit of normal&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  No unresolved adverse event from previous therapy&#xD;
&#xD;
          -  No prior radiotherapy to the head and neck&#xD;
&#xD;
          -  No prior or concurrent brachytherapy&#xD;
&#xD;
          -  No prior participation in this study&#xD;
&#xD;
          -  No T1 or T2 glottic tumors&#xD;
&#xD;
          -  No other serious concurrent medical illness&#xD;
&#xD;
          -  No history of insulin-dependent diabetes mellitus&#xD;
&#xD;
          -  No prior hypersensitivity reaction to yeast material&#xD;
&#xD;
          -  No recent history of oral ulceration, herpes simplex, oral candidiasis, severe&#xD;
             gingivitis, active or chronic mucositis, or xerostomia&#xD;
&#xD;
          -  No current New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No chemotherapy, radiotherapy, or other investigational drugs within the past 4 weeks&#xD;
&#xD;
          -  No major surgery within the past 2 weeks&#xD;
&#xD;
          -  No systemic sargramostim (GM-CSF) within the past 7 days&#xD;
&#xD;
          -  No systemic filgrastim (G-CSF) within the past 24 hours&#xD;
&#xD;
          -  No systemic long-acting pegfilgrastim within the past 14 days&#xD;
&#xD;
          -  No antibiotics, antifungals, or antivirals for oral conditions at baseline&#xD;
&#xD;
          -  No other concurrent chemotherapy agent&#xD;
&#xD;
          -  No concurrent enrollment on other head and neck studies&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent administration of any of the following:&#xD;
&#xD;
               -  &quot;Magic or miracle mouthwash&quot; containing a palliative mixture of topical&#xD;
                  anesthetics/analgesics, coating agents, and other medications without an approved&#xD;
                  indication for topical oral use except liquid antacid formulations (e.g., Maalox®&#xD;
                  or Mylanta® or their generic equivalents)&#xD;
&#xD;
               -  Other concurrent over-the-counter or prescription mouthwashes beyond the&#xD;
                  systematic oral care protocol provided by the study or any other drugs or agents&#xD;
                  to aid in oral hygiene (e.g., chlorhexidine, gluconate, pilocarpine, amifostine,&#xD;
                  sucralfate tablets or slurry, or benzydamine)&#xD;
&#xD;
               -  Use of corticosteroids for chronic conditions OR within the past 7 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marylin J. Dodd, RN, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <results_first_submitted>March 27, 2013</results_first_submitted>
  <results_first_submitted_qc>May 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2013</results_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Marilyn Dodd</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Recurrent squamous, basal cell carcinoma of the pharynx,larynx,lip</keyword>
  <keyword>Oropharynx, paranasal sinus and nasal cavity</keyword>
  <keyword>Stage I-IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>Stage I-IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>Recurrent esthesioneuroblastoma of paranasal sinus, nasal cavity</keyword>
  <keyword>Recurrent inverted papilloma of the paranasal sinus, nasal cavity</keyword>
  <keyword>Recurrent midline granuloma of the paranasal sinus, nasal cavity</keyword>
  <keyword>Untreated, current, metastatic squamous neck cancer</keyword>
  <keyword>Recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>Recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>Stage I verrucous carcinoma of the larynx</keyword>
  <keyword>Recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>Stage I verrucous carcinoma of the oral cavity</keyword>
  <keyword>Stage II verrucous carcinoma of the larynx</keyword>
  <keyword>Stage II verrucous carcinoma of the oral cavity</keyword>
  <keyword>Stage III verrucous carcinoma of the larynx</keyword>
  <keyword>Stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>Stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>Stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>Recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>Stage I adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>Stage II adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>Stage III adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>Stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>Recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>Stage I mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>Stage II mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>Stage III mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>Stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>Recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>Stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>Stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>Stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>Stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Tongue Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult (&gt; 18 years of age) with confirmed histopathological diagnosis of head and neck carcinoma were recruited at the University of California, San Francisco Radiation Oncology Clinic, the Helen Diller Comprehensive Cancer Center, Saint Francis Medical Center in San Francisco, and Temple University Radiation Oncology Clinic in Philadelphia from May 2005 to Dec 2009.</recruitment_details>
      <pre_assignment_details>Of 532 potential subjects that were screened, 374 were excluded as they did not meet the inclusion criteria, 45 refused to participate and 22 were no-shows (declined radiation therapy), thereby reducing our original target sample population to 91.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I: GM-CSF Group (GG)</title>
          <description>Arm I: Patients were randomized to receive oral sargramostim (GM-CSF) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
        </group>
        <group group_id="P2">
          <title>Arm II: Salt &amp; Soda Group (SS)</title>
          <description>Arm II: Patients were randomized to receive salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving SS treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
        </group>
        <group group_id="P3">
          <title>Arm III: Salt &amp; Soda Switched to GM-CSF (SG)</title>
          <description>Arm III: Patients were randomized to receive oral salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change Treatment Regimen (ineligible)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hypersensitive Reaction (to Salt &amp; Soda)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refuse Radiation Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Show</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Went back to his home country</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Blood clot after chemotherapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ischemic stroke after chemotherapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Possible Tracheostomy leakage</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Low radiation dose in oral cavity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I: GM-CSF Group (GG)</title>
          <description>Arm I: Patients receive oral sargramostim (GM-CSF) mouthwash, holding it in their mouths and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
        </group>
        <group group_id="B2">
          <title>Arm II: Salt &amp; Soda Group (SS)</title>
          <description>Arm II: Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
        </group>
        <group group_id="B3">
          <title>Arm III: Salt &amp; Soda Switched to GM-CSF (SG)</title>
          <description>Arm II patients are split, with Arm III being switched to GM-CSF when they develop mucositis.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.55" spread="13.73"/>
                    <measurement group_id="B2" value="54.69" spread="12.22"/>
                    <measurement group_id="B3" value="56.26" spread="11.29"/>
                    <measurement group_id="B4" value="54.48" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Number of Participants With Grade 1 or 2 Oral Mucositis (GM-CSF and SS Groups Only)</title>
        <description>The number of participants with recorded grade 1 (mild; Irritation, may experience slight pain, not requiring analgesic) or grade 2 (moderate; Patchy mucositis that may produce inflammatory serosanguinitis discharge; may experience moderate pain requiring analgesia) oral mucositis using the Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria Oral Mucosa Assessment Scale at baseline and during radiotherapy will be recorded. The RTOG grading is reliant on a clinician's ability to judge the anatomical changes associated with oral mucositis (size and characteristics of ulceration), with symptoms ranging from Grade 0 (no symptoms) to Grade 4 (Ulceration, hemorrhage, or necrosis). A comparison of incidence in the GM-CSF Group (GG) and Arm II: Salt &amp; Soda Group (SS) will be reported.</description>
        <time_frame>From baseline to onset of mucositis, approximately 16 days</time_frame>
        <population>Intent to treat population consisted of randomized subjects who completed baseline questionnaire and had at least one dose of mouthwash</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: GM-CSF Group (GG)</title>
            <description>Arm I: Patients receive oral sargramostim (GM-CSF) mouthwash, holding it in their mouths and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Salt &amp; Soda Group (SS)</title>
            <description>Arm II: Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Number of Participants With Grade 1 or 2 Oral Mucositis (GM-CSF and SS Groups Only)</title>
          <description>The number of participants with recorded grade 1 (mild; Irritation, may experience slight pain, not requiring analgesic) or grade 2 (moderate; Patchy mucositis that may produce inflammatory serosanguinitis discharge; may experience moderate pain requiring analgesia) oral mucositis using the Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria Oral Mucosa Assessment Scale at baseline and during radiotherapy will be recorded. The RTOG grading is reliant on a clinician's ability to judge the anatomical changes associated with oral mucositis (size and characteristics of ulceration), with symptoms ranging from Grade 0 (no symptoms) to Grade 4 (Ulceration, hemorrhage, or necrosis). A comparison of incidence in the GM-CSF Group (GG) and Arm II: Salt &amp; Soda Group (SS) will be reported.</description>
          <population>Intent to treat population consisted of randomized subjects who completed baseline questionnaire and had at least one dose of mouthwash</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact two tailed test</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Fisher Exact</method>
            <method_desc>Two by two table was used. One cell had expected frequency test less than five, so Fisher's exact two-tailed test was used.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of the Mean Number of Days for Mucositis to Heal Across by Group</title>
        <description>The mean number of days for mucositis to heal will be used to evaluate the effectiveness of the two mouthwashes in treating oral mucositis as defined by the incidence of Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring.</description>
        <time_frame>From onset of mucositis to healing of mucositis, approximately 80 days</time_frame>
        <population>Intent to treat population consisted of randomized subjects who completed baseline questionnaire and had at least one dose of mouthwash</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: GM-CSF Group (GG)</title>
            <description>Arm I: Patients receive oral sargramostim (GM-CSF) mouthwash, holding it in their mouths and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Salt &amp; Soda Group (SS)</title>
            <description>Arm II: Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
          </group>
          <group group_id="O3">
            <title>Arm III: Salt &amp; Soda Switched to GM-CSF (SG)</title>
            <description>Arm II patients are split, with Arm III being switched to GM-CSF when they develop mucositis.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Mean Number of Days for Mucositis to Heal Across by Group</title>
          <description>The mean number of days for mucositis to heal will be used to evaluate the effectiveness of the two mouthwashes in treating oral mucositis as defined by the incidence of Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring.</description>
          <population>Intent to treat population consisted of randomized subjects who completed baseline questionnaire and had at least one dose of mouthwash</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" spread="63.43"/>
                    <measurement group_id="O2" value="79.4" spread="31.24"/>
                    <measurement group_id="O3" value="77.4" spread="37.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier estimate of the survival curves used information from subjects who develop mucositis to the healing of the mucositis in three groups, Group GG, SS, and SG. In order to compare the three curves that were created, the Mantel-Haenszel log-rank statistic was used</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Log rank, Breslow, Tarone-Ware test, but used mantel cox log rank for this analysis</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of the Combined Mean Score on the Overall Quality of Life Questionnaires by Group</title>
        <description>Quality of life at baseline, during radiotherapy, and once a month for 3 months after radiotherapy. The items on the quality of life questionnaire developed for the study range in scores from 0-10 with higher scores indicating a better quality of life. Scores at all time points were combined to compute one mean score for overall quality of life during the study.</description>
        <time_frame>Up to 3 months</time_frame>
        <population>Of the intent to treat population, subjects who did not fill out the baseline quality of life questionnaires were not included in our analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: GM-CSF Group (GG)</title>
            <description>Arm I: Patients receive oral sargramostim (GM-CSF) mouthwash, holding it in their mouths and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Salt &amp; Soda Group (SS)</title>
            <description>Arm II: Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
          </group>
          <group group_id="O3">
            <title>Arm III: Salt &amp; Soda Switched to GM-CSF (SG)</title>
            <description>Arm II patients are split, with Arm III being switched to GM-CSF when they develop mucositis.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Combined Mean Score on the Overall Quality of Life Questionnaires by Group</title>
          <description>Quality of life at baseline, during radiotherapy, and once a month for 3 months after radiotherapy. The items on the quality of life questionnaire developed for the study range in scores from 0-10 with higher scores indicating a better quality of life. Scores at all time points were combined to compute one mean score for overall quality of life during the study.</description>
          <population>Of the intent to treat population, subjects who did not fill out the baseline quality of life questionnaires were not included in our analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.91" spread="1.59"/>
                    <measurement group_id="O2" value="6.80" spread="1.46"/>
                    <measurement group_id="O3" value="6.77" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Multilevel regression was used.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.28</p_value>
            <p_value_desc>0.28 (quadratic)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted Maximum Likelihood Methods with random intercepts was the only model used for the three groups and seven measurement time points.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Combined Mean Score on the Karnofsky Performance Status Scale (KPS) by Group</title>
        <description>Functional status of participants was measured by administering the KPS which contains items asking about performing daily activities. The scores are grouped in 10s ranging from 100 (Normal, no complaints) to 0 (Dead), with higher scores indicating better functional status. The KPS was administered at baseline, during radiotherapy, and once a month for 3 months after radiation therapy. Scores at all time points were combined to compute one mean to determine overall performance status during the course of the study.</description>
        <time_frame>Up to 3 months</time_frame>
        <population>Of the intent to treat population, subjects who did not fill out the baseline Karnofsky functional scales were not included in our analysis. They withdrew from the study after signing the consent forms for personal reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: GM-CSF Group (GG)</title>
            <description>Arm I: Patients receive oral sargramostim (GM-CSF) mouthwash, holding it in their mouths and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Salt &amp; Soda Group (SS)</title>
            <description>Arm II: Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
          </group>
          <group group_id="O3">
            <title>Arm III: Salt &amp; Soda Switched to GM-CSF (SG)</title>
            <description>Arm II patients are split, with Arm III being switched to GM-CSF when they develop mucositis.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Combined Mean Score on the Karnofsky Performance Status Scale (KPS) by Group</title>
          <description>Functional status of participants was measured by administering the KPS which contains items asking about performing daily activities. The scores are grouped in 10s ranging from 100 (Normal, no complaints) to 0 (Dead), with higher scores indicating better functional status. The KPS was administered at baseline, during radiotherapy, and once a month for 3 months after radiation therapy. Scores at all time points were combined to compute one mean to determine overall performance status during the course of the study.</description>
          <population>Of the intent to treat population, subjects who did not fill out the baseline Karnofsky functional scales were not included in our analysis. They withdrew from the study after signing the consent forms for personal reasons.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.52" spread="12.61"/>
                    <measurement group_id="O2" value="82.93" spread="10.92"/>
                    <measurement group_id="O3" value="83.49" spread="12.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.78</p_value>
            <p_value_desc>0.78 (quadratic)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted Maximum Likelihood Methods with random intercepts was the only model used for the three groups and seven measurement time points.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Combined Mean Score on the Pain Questionnaire by Group</title>
        <description>Severity and quality of pain was measured using a pain questionnaire developed for this study with total scores ranging from 0 (no pain) to 10 (most intense pain) with higher scores indicating a greater level of pain. The questionnaire was administered at baseline, during radiotherapy, and once a month for 3 months after radiotherapy. Scores at all time points were combined to compute one mean to determine overall pain intensity score during the course of the study</description>
        <time_frame>Up to 3 months</time_frame>
        <population>Of the intent to treat population, subjects who did not fill out the baseline pain questionnaires were not included in our analysis. They withdrew from the study after signing the consent forms for personal reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: GM-CSF Group (GG)</title>
            <description>Arm I: Patients receive oral sargramostim (GM-CSF) mouthwash, holding it in their mouths and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Salt &amp; Soda Group (SS)</title>
            <description>Arm II: Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
          </group>
          <group group_id="O3">
            <title>Arm III: Salt &amp; Soda Switched to GM-CSF (SG)</title>
            <description>Arm II patients are split, with Arm III being switched to GM-CSF when they develop mucositis.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Combined Mean Score on the Pain Questionnaire by Group</title>
          <description>Severity and quality of pain was measured using a pain questionnaire developed for this study with total scores ranging from 0 (no pain) to 10 (most intense pain) with higher scores indicating a greater level of pain. The questionnaire was administered at baseline, during radiotherapy, and once a month for 3 months after radiotherapy. Scores at all time points were combined to compute one mean to determine overall pain intensity score during the course of the study</description>
          <population>Of the intent to treat population, subjects who did not fill out the baseline pain questionnaires were not included in our analysis. They withdrew from the study after signing the consent forms for personal reasons.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="2.40"/>
                    <measurement group_id="O2" value="1.72" spread="2.26"/>
                    <measurement group_id="O3" value="2.15" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.22</p_value>
            <p_value_desc>0.22 (quadratic)</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted Maximum Likelihood Methods with random intercepts was the only model used for the three groups and seven measurement time points.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 months</time_frame>
      <desc>Serious Adverse Events and adverse events were collected in the safety population which is comprised of all participants who were both randomized and received at least one dose of the study medication. Number of participants at risk represents the number of participants who received study medications.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I: GM-CSF Group (GG)</title>
          <description>Arm I: Patients receive oral sargramostim (GM-CSF) mouthwash, holding it in their mouths and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
        </group>
        <group group_id="E2">
          <title>Arm II: Salt &amp; Soda Group (SS)</title>
          <description>Arm II: Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily. Treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.</description>
        </group>
        <group group_id="E3">
          <title>Arm III: Salt &amp; Soda Switched to GM-CSF (SG)</title>
          <description>Arm II patients are split, with Arm III being switched to GM-CSF when they develop mucositis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis Oral</sub_title>
                <description>Mucositis Oral:Hypersensitivity Reaction from Salt and Soda Mouthwash</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>Other (withdrawal symptoms-opioid)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>Reactive oral mucositis : Due to the timing of the adverse event (AE), the study team determined that the reactive oral mucositis is unlikely to be related to radiation therapy and was part of the salt and soda group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Transfusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <description>Sinus tachycardia due to Acetaminophen-codeine medication.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>(Shoulder and neck area)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>(Withdraweal symptoms-opioid)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound infection</sub_title>
                <description>(Right foot)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>(left parotid gland)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <description>(bicycle accident)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Radiation dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>(&gt;15 lbs; more than 10%)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>(hydrated at doctor's office during/after radiation treatment)</description>
                <counts group_id="E1" events="16" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" events="27" subjects_affected="13" subjects_at_risk="28"/>
                <counts group_id="E3" events="21" subjects_affected="10" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exostosis</sub_title>
                <description>Had the potential to have bone growth and had previous history. Based on physician's decision. Patient was in Salt and Soda group. This was not related to the mouth wash medication.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemia Cerebrovascular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>(chest congestion)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Laryngopharyngeal Dyesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Laryngeal obstruction</sub_title>
                <description>(mucous)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Laryngeal edema</sub_title>
                <description>(Asymptomatic; clinical observations only; intervention not indicated; tracheostomy area)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>(due to fentanyl patch)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Rash acne form</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>(lung biopsy)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>(Percutaneous endoscopic gastrostomy tube insertion)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>(PEG tube removal)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>(basal cell carcinoma remove from thumb)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>(facial reconstruction)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>(Septoplasty)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marylin J. Dodd, RN, PhD, FAAN</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-476-2191</phone>
      <email>Marylin.dodd@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

